Bolt Biotherapeutics Q3 2023: cash $141.4M, BDC-1001 29% ORR, BDC-3042 dosed

Bolt Biotherapeutics, Inc.

2023-Q3 EPS reported -$1.36 revenue$5,787,000

Cash, cash equivalents and marketable securities of $141.4M as of Sept 30, 2023; expected to fund operations through 2025.
Collaboration revenue $2.5M (vs $2.1M Q3 2022); R&D expenses $15.0M (down from $19.0M).
Loss from operations of $18.2M vs $22.3M in prior year quarter.
BDC-1001 Phase 1 updated data: 29% ORR monotherapy; first complete response; well tolerated; Orphan Drug Designation for gastric cancers.
First patient dosed with BDC-3042 in Phase 1/2 for advanced solid tumors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bolt Biotherapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $2.5 million.

Period: the third quarter ended September 30, 2023
Revenue: $2.5 million
Result: reported results

Exact text from the filing

2023. Cash on hand is expected to fund multiple milestones and operations through 2025. Third Quarter 2023 Financial Results • Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022. Revenue in the comparative periods were generated from the services performed

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.